PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Safinamide - Parkinson's disease
PAD Profile : Safinamide - Parkinson's disease
Keywords :
PD
Brand Names Include :
Xadago
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Tolcapone
- Apomorphine hydrochloride
- Opicapone
- Co-beneldopa (Benserazide/levodopa)
- Co-careldopa (Carbidopa/levodopa)
- Pramipexole
- Ropinirole hydrochloride
- Bromocriptine
- Pergolide mesilate
- Cabergoline
- Rasagiline mesilate
- Selegiline hydrochloride
- Entacapone
- Amantadine hydrochloride
- Orphenadrine hydrochloride
- Procyclidine hydrochloride
- Trihexyphenidyl hydrochloride
- Clonazepam
- Melatonin
- Rotigotine
- Levodopa/carbidopa/entacapone
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Policy Statement
Safinamide as add on therapy to Levodopa alone or in combination to other treatments in adult patien
01 June 2025
Committee Recommendations
Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
22 January 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Prescribing Clinical Network does not recommend Safinamide as add on therapy to Levodopa, alone or in combination to other treatments in adult patients with idiopathic Parkinson’s Disease
Safinamide will be considered BLACK on the traffic light status for all new patients as there are more cost effective treatment options available.
Patients whose treatment with safinamide was initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.
Associated BNF Codes
04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism